lncRNAs as prognostic molecular biomarkers in hepatocellular carcinoma: a systematic review and meta-analysis.
lncRNAs as prognostic molecular biomarkers in hepatocellular carcinoma: a systematic review and meta-analysis.
复制标题
lncRNA作为肝细胞癌的预后分子生物标志物：系统评价和荟萃分析
DOI：
10.18632/oncotarget.19559
复制
发表时间：
2017-08-29
期刊：
影响因子：
--
通讯作者：
Shao J
中科院分区：
文献类型：
--
作者：
Zheng C;Liu X;Chen L;Xu Z;Shao J
最新研究表明，长链非编码RNA（lncRNA）在肿瘤中表达异常，可作为肿瘤预后的分子生物标志物。在这项研究中，我们的目的是评估lncRNA作为肝细胞癌患者的预后价值。我们对PubMed和Embase数据库中关于各种lncRNA在HCC中的预后价值的文章进行了详细的检索。然后，我们仔细地提取了相关的数据，我们使用荟萃分析方法来分析这些结果，并评估异质性和发表偏倚。共纳入40项相关研究，发现27种lncRNA高表达与HCC患者预后不良相关，18种lncRNA低表达与HCC患者预后不良相关。lncRNA表达较高的患者总生存期显著较差（OS;合并HR，1.25; 95%置信区间[CI]，1.03-1.52），无复发生存期显著较差（RFS;合并HR，1.66; 95% CI，1.26-2.17）。lncRNA的过表达可能无法有意义地预测无病生存期（DFS;合并HR，1.04; 95% CI，0.52-2.07; p = 0.91）。我们的荟萃分析表明，lncRNA可以作为癌症预后的预测生物标志物。
The latest studies have shown that long non-coding RNAs (lncRNAs) may be considered markers as their expression levels were abnormal in cancer and can be used as a molecular biomarker for the potential assessment of cancer prognosis. In this study, we aimed to assess the prognostic value of lncRNA as marker of patients with hepatocellular carcinoma. We performed a detailed search of the PubMed and Embase databases for articles on the prognostic value of various lncRNAs in HCC. We then carefully extracted the relevant data from the articles, and we used the meta-analysis method to analyze these results; heterogeneity and publication bias were also evaluated. With 40 associative studies included, we found that high expression of 27 types of lncRNA was associated with a poor prognosis in HCC patients, and low expression of 18 types of lncRNAs was associated with a worse prognosis. Patients with higher lncRNA expression had significantly poor overall survival (OS; pooled HR, 1.25; 95% confidence interval [CI], 1.03–1.52) as well as significantly poor recurrence-free survival (RFS; pooled HR, 1.66; 95% CI, 1.26–2.17). Overexpression of lncRNAs may not meaningfully predict disease-free survival (DFS; pooled HR, 1.04; 95% CI, 0.52–2.07; p = 0.91). Our meta-analysis demonstrated that lncRNAs may serve as predictive biomarkers for cancer prognosis.